These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38574584)

  • 1. PET brain imaging in neurological disorders.
    Xie L; Zhao J; Li Y; Bai J
    Phys Life Rev; 2024 Jul; 49():100-111. PubMed ID: 38574584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications of positron emission tomography in animal models of neurological and neuropsychiatric disorders.
    Virdee K; Cumming P; Caprioli D; Jupp B; Rominger A; Aigbirhio FI; Fryer TD; Riss PJ; Dalley JW
    Neurosci Biobehav Rev; 2012 Apr; 36(4):1188-216. PubMed ID: 22342372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography imaging in neurological disorders.
    Politis M; Piccini P
    J Neurol; 2012 Sep; 259(9):1769-80. PubMed ID: 22297461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET molecular imaging in stem cell therapy for neurological diseases.
    Wang J; Tian M; Zhang H
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1926-38. PubMed ID: 21698414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiopharmaceuticals in neurological and psychiatric disorders.
    Valotassiou V; Wozniak G; Sifakis N; Demakopoulos N; Georgoulias P
    Curr Clin Pharmacol; 2008 May; 3(2):99-107. PubMed ID: 18690884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography applications in clinical neurology.
    Singhal T
    Semin Neurol; 2012 Sep; 32(4):421-31. PubMed ID: 23361486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.
    Mosconi L
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):486-510. PubMed ID: 15747152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional brain imaging: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(22):1-79. PubMed ID: 23074493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET imaging of neuroinflammation in neurological disorders.
    Kreisl WC; Kim MJ; Coughlin JM; Henter ID; Owen DR; Innis RB
    Lancet Neurol; 2020 Nov; 19(11):940-950. PubMed ID: 33098803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status and future challenges of brain imaging with (18)F-DOPA PET for movement disorders.
    Calabria FF; Calabria E; Gangemi V; Cascini GL
    Hell J Nucl Med; 2016; 19(1):33-41. PubMed ID: 26929938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron Emission Tomography Molecular Imaging of the Major Neurodegenerative Disorders: Overview and Pictorial Essay, from a Nuclear Medicine Center's Perspective.
    Calabria F; Leporace M; Cimini A; Ricci M; Travascio L; Bagnato A
    J Integr Neurosci; 2023 Dec; 22(6):172. PubMed ID: 38176937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET imaging in neurology: Alzheimer's and Parkinson's diseases.
    Sarikaya I
    Nucl Med Commun; 2015 Aug; 36(8):775-81. PubMed ID: 25920047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET imaging of reactive astrocytes in neurological disorders.
    Liu Y; Jiang H; Qin X; Tian M; Zhang H
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1275-1287. PubMed ID: 34873637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases.
    Dupont AC; Largeau B; Santiago Ribeiro MJ; Guilloteau D; Tronel C; Arlicot N
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28387722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioligand imaging of α4β2* nicotinic acetylcholine receptors in Alzheimer's disease and Parkinson's disease.
    Meyer PM; Tiepolt S; Barthel H; Hesse S; Sabri O
    Q J Nucl Med Mol Imaging; 2014 Dec; 58(4):376-86. PubMed ID: 25387119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiopharmaceuticals in positron emission tomography: present situation and future perspectives.
    Olivas Arroyo C
    Radiologia; 2016; 58(6):468-480. PubMed ID: 27592111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative positron emission tomography in brain research.
    Heurling K; Leuzy A; Jonasson M; Frick A; Zimmer ER; Nordberg A; Lubberink M
    Brain Res; 2017 Sep; 1670():220-234. PubMed ID: 28652218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of positron emission tomography imaging in understanding Alzheimer's disease.
    Barthel H; Seibyl J; Sabri O
    Expert Rev Neurother; 2015 Apr; 15(4):395-406. PubMed ID: 25752209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain
    Nobili F; Arbizu J; Bouwman F; Drzezga A; Agosta F; Nestor P; Walker Z; Boccardi M;
    Eur J Neurol; 2018 Oct; 25(10):1201-1217. PubMed ID: 29932266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging Cholinergic Receptors in the Brain by Positron Emission Tomography.
    Zhang JJ; Fu H; Lin R; Zhou J; Haider A; Fang W; Elghazawy NH; Rong J; Chen J; Li Y; Ran C; Collier TL; Chen Z; Liang SH
    J Med Chem; 2023 Aug; 66(16):10889-10916. PubMed ID: 37583063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.